Fujifilm Diosynth Biotechnologies Opens New Manufacturing Facility - - BioPharm International

ADVERTISEMENT

Fujifilm Diosynth Biotechnologies Opens New Manufacturing Facility


Fujifilm Diosynth Biotechnologies formally opened its new mammalian cell culture cGMP manufacturing facility in the United Kingdom, the company reported in a press release. The new facility, which was built and commissioned in less than 15 months, is the first facility of its kind in the UK that was purpose-built to use primarily single-use technologies for both upstream and downstream operations. It has initially been commissioned with 200-L and 1000-L bioreactors, with a 2000-L bioreactor planned for 2014. The company is working on its first customer project for the facility.

This new capacity is the latest in a series of investments at both Fujifilm Diosynth Biotechnologies’ UK and Research Triangle Park, NC, US facilities over the past two years. New cell-line development and process-development laboratories have been set up at both sites, and a 1000-L single-use bioreactor was installed at the US facility two years ago to supplement its 2000-L stainless-steel train for the GMP production of mammalian cell-culture biopharmaceuticals.

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Yale and Gilead Extend Sequencing Initiative
October 28, 2014
Contract Research and Manufacturing Organization Paragon Bioservices Raises $13 Million
October 28, 2014
Author Guidelines

Click here